The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...
Switching from aflibercept to ranibizumab biosimilars maintains stability in nAMD treatment, offering a cost-effective ...
Explore the safety and efficacy of switching to etanercept biosimilars, backed by clinical trials and real-world evidence for ...
FDA approves new denosumab biosimilars, enhancing treatment options for osteoporosis and bone metastases while driving ...
There are critical gaps in biosimilar adoption for pediatric patients, focusing on safety, regulatory challenges, and the ...
Biosimilar partnerships and EU approvals surge, enhancing access to innovative treatments in immunology, oncology, and bone ...
Explore the latest developments in the US biosimilar market, highlighting key approvals, challenges, and future trends ...
A retrospective observational study found no significant differences in progression-free survival or safety in patients with colorectal cancers in Japan treated with ABP 215, Amgen’s bevacizumab ...
April E. Weisbruch is a partner at McDermott, Will, & Emery LLP. She focuses her practice on intellectual property (IP) matters, particularly in managing large-scale IP litigation and counseling. She ...
Discover the top 5 regulatory biosimilar news of 2025, highlighting FDA approvals that enhance treatment options and competition in health care. In 2025, the FDA continued to rapidly expand access to ...
Tyruko, the first natalizumab biosimilar for multiple sclerosis, promises significant savings and competition in the US market. The launch of natalizumab-sztn (Tyruko) marked a milestone for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback